<p>Paraneoplastic neurological syndromes (PNS) represent a rare but clinically significant group of disorders that arise as indirect effects of cancer through immune-mediated mechanisms. They differ from direct tumor invasion, metastasis, or treatment-related toxicity, and often precede cancer diagnosis, making early recognition essential. This review outlines the distinctions between carcinoid syndrome, paraneoplastic endocrine/metabolic syndromes, and PNS, highlighting their clinical relevance in oncology education. We summarize current knowledge on the pathophysiology, clinical spectrum, diagnostic approaches, and management strategies for PNS. Emphasis is placed on their educational value as models for interdisciplinary learning, diagnostic reasoning, and integration of oncology with neurology. Improved awareness among medical trainees and oncologists can enhance early detection, appropriate management, and patient outcomes.</p>